Merck (MRK) Liabilities and Shareholders Equity (2009 - 2026)

Merck has disclosed Liabilities and Shareholders Equity across 18 years of filings, most recently posting $128.7 billion for Q1 2026.

• In Q1 2026, Liabilities and Shareholders Equity rose 11.78% year-over-year to $128.7 billion; the TTM figure through Mar 2026 stood at $512.6 billion (up 10.86% YoY), while the FY2025 annual figure was $136.9 billion, up 16.87% from the prior year.
• Liabilities and Shareholders Equity fell to $128.7 billion in Q1 2026, from $136.9 billion in the prior quarter.
• Over the last five years, Liabilities and Shareholders Equity for MRK reached as high as $136.9 billion in Q4 2025 and fell as low as $104.5 billion in Q2 2023.
• The 5-year median for Liabilities and Shareholders Equity is $109.2 billion (2022), against an average of $113.9 billion.
• Annual changes were most pronounced in 2022 — Liabilities and Shareholders Equity advanced 18.09% — and 2023, when it retreated 2.45%.
• A 5-year view of Liabilities and Shareholders Equity shows it stood at $109.2 billion in 2022, then retreated by 2.28% to $106.7 billion in 2023, then gained by 9.78% to $117.1 billion in 2024, then gained by 16.87% to $136.9 billion in 2025, then decreased by 5.98% to $128.7 billion in 2026.
• According to Business Quant data, Liabilities and Shareholders Equity over the past three periods registered $128.7 billion, $136.9 billion, and $129.5 billion for Q1 2026, Q4 2025, and Q3 2025 respectively.